Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Switching on cancer’s viral alarm system
19 May 2026
Publications
The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies
Journal article
Strain R. et al, (2026), Hepatology, 83, 1540 - 1556
The embryonic origins of site-specific arthritis.
Journal article
Davidson S. et al, (2026), Nature immunology
Hypoxia differentially affects coronary vessel formation during heart development.
Journal article
Payne S. et al, (2026), Cardiovascular research
Seminars
Somatic mitochondrial DNA mutations in cancer: prevalent and relevant
Monday, 22 June 2026, 11am to 12pm
Speaker(s): Prof Payam Gammage
conference
